Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer’s COVID-19 Vaccine Filed for Children 5 to 11 in Japan
November 10, 2021
- Otsuka, Takara Bio to Call Off Collaboration for Two Drug Candidates
November 10, 2021
- MSD Launches Antibiotic Recarbrio in Japan
November 10, 2021
- 6 Wholesalers Raided over Suspected Bid-Rigging in Kyushu
November 10, 2021
- Japan Ethical Drug Sales Rise 4.0% in September: Crecon
November 9, 2021
- Lilly, Torii to Wind Up Taltz Marketing Collaboration in Japan
November 9, 2021
- Ono’s BTK Inhibitor Velexbru Approved in South Korea
November 9, 2021
- Takecab Top-Seller Medicine in Japan in October: Encise
November 8, 2021
- AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses
November 8, 2021
- New EA Pharma CEO Eager to Put Company Back on Growth Track by Boosting Its Sales Strength
November 5, 2021
- Nippon Shinyaku Establishes Local Subsidiary in Beijing
November 5, 2021
- Ferring, Fuji Pharma Tie Up for Cervical Ripening Agent Propess
November 5, 2021
- Enhertu Application Accepted in Europe for 2nd Line Gastric Cancer: Daiichi Sankyo/AZ
November 5, 2021
- Plunge in COVID-19 Cases Stalling Japan Avigan Study by Few Months
November 5, 2021
- Otsuka’s In-Vitro Diagnostic for ALL Now under Health Coverage
November 4, 2021
- Axcelead Inks Research Pact with Kyowa Kirin, xFOREST on Drugs Targeting RNA Structures
November 4, 2021
- Fuji Pharma Files Contraceptive in Thailand
November 4, 2021
- Mitsubishi Tanabe Sales Rise 1.9% in 1st Half on Stelara Growth at Home
November 4, 2021
- 7 Major Japan Drug Makers Net Two-Digit Growth in Combined H1 Sales on Flagship Brands, Upfront Income
November 4, 2021
- LEO Pharma Japan Taps Ex-Sanofi Exec Kazushige Sakamoto as New Chief
November 4, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…